Jean-Pierre Lindenmayer, MD

Effects of a Digital Medicine System on Psychiatric Hospitalization Rates for Adults With Schizophrenia

April 11, 2022

This clinical trial investigated whether hospitalization rates improved when patients with schizophrenia were treated via a digital medicine system (aripiprazole tablets with sensor) versus oral standard-of-care therapy.

Elan A. Cohen, Taisa Skubiak, Dusica Hadzi Boskovic, et al

Consensus Statement

Screening, Diagnosis, and Treatment of Tardive Dyskinesia

January 28, 2020

Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.

Stanley N. Caroff, Leslie Citrome, Jonathan Meyer, et al

Commentary

Treatment-Resistant Schizophrenia Guideline

March 5, 2019

Read expert commentary on guidelines for treatment-resistant schizophrenia (TRS) to make more informed treatment decisions.

John M. Kane, Ofer Agid, Marjorie L. Baldwin, et al

Original Research

Antipsychotic Therapy in Schizophrenia

April 14, 2015

Read a study discussing Real-World Outcomes of Paliperidone Palmitate compared to Daily Oral Antipsychotic Therapy in Schizophrenia.

Larry Alphs, Carmela Benson, Kimberly Cheshire-Kinney, et al

Original Research

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

December 5, 2014

Dong-Jing Fu, Ibrahim Turkoz, R. Bruce Simonson, et al

Original Research

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

May 15, 2010

Carla M. Canuso, Jean-Pierre Lindenmayer, Colette Kosik-Gonzalez, et al

Original Research

Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment: A Randomized 5-Month Study

October 6, 2009

Robert C. Smith, Jean-Pierre Lindenmayer, John M. Davis, et al

Original Research

Outcome Evaluation of a Structured Educational Wellness Program in Patients With Severe Mental Illness

September 22, 2009

Jean-Pierre Lindenmayer, Anzalee Khan, Deborah Wance, et al

Original Research

Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response

June 2, 2009

Jean-Pierre Lindenmayer, Hong Liu-Seifert, Pandurang M. Kulkarni, et al

Letter to the Editor

Aripiprazole-Induced Agitation After Clozapine Discontinuation: A Case Report

May 15, 2009

Dara Y. Cho, Jean-Pierre Lindenmayer

Article

Modafinil as an Adjunctive Treatment of Sedation, Negative Symptoms, and Cognition in Schizophrenia: A Critical Review

November 18, 2008

Carlos Saavedra-Velez, Anna Yusim, Deepti Anbarasan, et al

Letter to the Editor

Efficacy of Molindone in Treatment-Refractory Agitated Schizophrenia: Three Case Reports

June 30, 2008

Michael Ciranni, Jean-Pierre Lindenmayer, Jeffrey Goldx

Effects of a Digital Medicine System on Psychiatric Hospitalization Rates for Adults With Schizophrenia

Screening, Diagnosis, and Treatment of Tardive Dyskinesia

Treatment-Resistant Schizophrenia Guideline

Antipsychotic Therapy in Schizophrenia

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment: A Randomized 5-Month Study

Outcome Evaluation of a Structured Educational Wellness Program in Patients With Severe Mental Illness

Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response

Aripiprazole-Induced Agitation After Clozapine Discontinuation: A Case Report

Modafinil as an Adjunctive Treatment of Sedation, Negative Symptoms, and Cognition in Schizophrenia: A Critical Review

Efficacy of Molindone in Treatment-Refractory Agitated Schizophrenia: Three Case Reports

ELSEWHERE:

FOLLOW US:

Jean-Pierre Lindenmayer, MD

Effects of a Digital Medicine System on Psychiatric Hospitalization Rates for Adults With Schizophrenia

Screening, Diagnosis, and Treatment of Tardive Dyskinesia

Treatment-Resistant Schizophrenia Guideline

Antipsychotic Therapy in Schizophrenia

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment: A Randomized 5-Month Study

Outcome Evaluation of a Structured Educational Wellness Program in Patients With Severe Mental Illness

Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response

Aripiprazole-Induced Agitation After Clozapine Discontinuation: A Case Report

Modafinil as an Adjunctive Treatment of Sedation, Negative Symptoms, and Cognition in Schizophrenia: A Critical Review

Efficacy of Molindone in Treatment-Refractory Agitated Schizophrenia: Three Case Reports

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles